SCHEMBL4356560

SCHEMBL4356560

COc1cc(C=CC=C2SC(N3CCSCC3)=NC2=O)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.61
KMT2A Q03164 9/20 0.61
GAA P10253 2/20 0.61
GFER P55789 1/20 0.61
GRIN1 Q05586 1/20 0.56
GRIN2B Q13224 1/20 0.56
TRPV1 Q8NER1 1/20 0.52
MAPT P10636 4/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
MCHR1 Q99705 1/20 0.51
DNMT1 P26358 1/20 0.50
PSMD14 O00487 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
XDH P47989 1/20 0.46
TXNRD1 Q16881 1/20 0.45
HPGD P15428 2/20 0.44
POLB P06746 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352294 0.88 MEN1 (0.78) MEN1KMT2AGAAGFERGRIN1
SCHEMBL4352297 0.88 MEN1 (0.78) MEN1KMT2AGAAGFERGRIN1
SCHEMBL822697 0.81 MEN1 (0.84) MEN1KMT2AGAAGFERGRIN1
SCHEMBL2199726 0.78 MCHR1 (0.82) MEN1KMT2AGAAGFERGRIN1
SCHEMBL2199730 0.78 MCHR1 (0.82) MEN1KMT2AGAAGFERGRIN1
SCHEMBL4359181 0.78 MAPT (0.81) MEN1KMT2AGRIN1GRIN2BMAPT
SCHEMBL4348827 0.77 MEN1 (0.76) MEN1KMT2AGAAGFERGRIN1
SCHEMBL4348152 0.77 MEN1 (0.76) MEN1KMT2AGAAGFERGRIN1
SCHEMBL4348150 0.77 MEN1 (0.76) MEN1KMT2AGAAGFERGRIN1
SCHEMBL4348830 0.77 MEN1 (0.76) MEN1KMT2AGAAGFERGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MEN1 1725/4885KMT2A 3923/4885GAA 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.